Pacira Pharmaceuticals, Inc. Forecast, price target & analysts
Pacira Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Pacira Pharmaceuticals, Inc. Classifications & Recommendation
Pacira Pharmaceuticals, Inc. Price Target
| Target Price | $28.05 |
| Price | $24.69 |
| Potential |
13.61%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Pacira Pharmaceuticals, Inc. 2027 .
The average Pacira Pharmaceuticals, Inc. target price is $28.05.
This is
13.61%
register free of charge
$39.90
61.60%
register free of charge
$23.23
5.91%
register free of charge
|
|
| A rating was issued by 13 analysts: 9 Analysts recommend Pacira Pharmaceuticals, Inc. to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pacira Pharmaceuticals, Inc. stock has an average upside potential 2027 of
13.61%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 726.41 | 767.47 |
| 3.63% | 5.65% | |
| EBITDA Margin | 13.21% | 24.26% |
| 41.87% | 83.63% | |
| Net Margin | 0.97% | 15.26% |
| 106.81% | 1,476.82% |
9 Analysts have issued a sales forecast Pacira Pharmaceuticals, Inc. 2026 . The average Pacira Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Pacira Pharmaceuticals, Inc. EBITDA forecast 2026. The average Pacira Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Pacira Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Pacira Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.16 | 2.94 |
| 107.44% | 1,737.50% | |
| P/E | 8.39 | |
| EV/Sales | 1.43 |
9 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast for earnings per share. The average Pacira Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Pacira Pharmaceuticals, Inc....
Current Pacira Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 09 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 05 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 01 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | May 01 2026 |
| Needham |
Locked
➜
Locked
|
Locked | May 01 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Mar 26 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 09 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 05 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 01 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
May 01 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
May 01 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Mar 26 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
